Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Evidence so far indicates that therapies targeting a single aspect of Alzheimer's disease (AD) have no sufficient efficacy in diminishing long-term the progression of AD. Neuroinflammation is an early event during the development of the disease and it is thought to exacerbate the abnormal aggregation of the amyloid beta peptide (Aβ) and the microtubule associated protein Tau. Inhibition of gliosis is considered fundamental to reduce neuroinflammation, oxidative stress, apoptosis and synaptic dysfunction driving the progression of AD. Drugs that are able to target more than one aspect of the pathology may have higher chances of success. Modulators of α7 nicotinic acetylcholine receptors (α7nAChRs) such as nicotine and some of its derivatives have this potential because of their anti-inflammatory, anti-apoptotic, pro-cognitive and anti-protein aggregation effects. However, the rapid desensitization of α7nAChRs is considered an important factor limiting its potential therapeutic use. In here, in light of current evidence, the objective of this review is to discuss the advantages and potential therapeutic value of positive allosteric modulators (PAMs) of the nAChRs in halting or delaying the progression of AD by diminishing neuroinflammation, abnormal protein aggregation and synaptic dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
ATP mediates rapid microglial response to local brain injury in vivo
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L., & Gan, W.-B. (2005) · Nature Neuroscience · doi:10.1038/nn1472 · Cited by 3,913
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., et al. (2003) · Nature · doi:10.1038/nature01339 · Cited by 3,228
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Research works printed but not linked: 183
- Abdul, 2009, Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling, J. Neurosci., 29, 12957, 10.1523/JNEUROSCI.1064-09.2009 · DOI · Paper page
- Ahmad, 2006, Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity, J. Neurotrauma, 23, 1895, 10.1089/neu.2006.23.1895 · DOI
- Ahmad, 2006, 1-hydroxyPGE reduces infarction volume in mouse transient cerebral ischemia, Eur. J. Neurosci., 23, 35, 10.1111/j.1460-9568.2005.04540.x · DOI
- Akiyama, 2000, Inflammation and Alzheimer's disease, Neurobiol. Aging, 21, 383, 10.1016/S0197-4580(00)00124-X · DOI · Paper page
- Aliev, 2003, Hypoperfusion, mitochondria failure, oxidative stress, and alzheimer disease, J. Biomed. Biotechnol., 2003, 162, 10.1155/S1110724303305029 · DOI
- Alkadhi, 2011, Chronic psychosocial stress exacerbates impairment of synaptic plasticity in beta-amyloid rat model of Alzheimer's disease: prevention by nicotine, Curr. Alzheimer Res., 8, 718, 10.2174/156720511797633188 · DOI · Paper page
- Alkadhi, 2010, Intensification of long-term memory deficit by chronic stress and prevention by nicotine in a rat model of Alzheimer's disease, Mol. Cell Neurosci., 45, 289, 10.1016/j.mcn.2010.06.018 · DOI
- Amin, 2014, Effect of Abeta immunisation on hyperphosphorylated tau: a potential role for GSK-3beta, Neuropathol. Appl. Neurobiol., 41, 445, 10.1111/nan.12205 · DOI
- Appel, 1981, A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease, Ann. Neurol., 10, 499, 10.1002/ana.410100602 · DOI · Paper page
- Aronson, 2009, Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial, Drugs Aging, 26, 231, 10.2165/00002512-200926030-00004 · DOI
- Association, 2015, Alzheimer's Association Report 2015 Alzheimer's disease facts and figures, Alzheimer's Dement., 11, 332, 10.1016/j.jalz.2015.02.003 · DOI · Paper page
- Bagaitkar, 2012, Cotinine inhibits the pro-inflammatory response initiated by multiple cell surface Toll-like receptors in monocytic THP cells, Tob. Induc. Dis., 10, 18, 10.1186/1617-9625-10-18 · DOI
- Bales, 1998, The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation, Brain Res. Mol. Brain Res., 57, 63, 10.1016/S0169-328X(98)00066-7 · DOI · Paper page
- Barreto, 2015, Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease, Front. Aging Neurosci., 6, 340, 10.3389/fnagi.2014.00340 · DOI
- Beach, 1989, Patterns of gliosis in Alzheimer's disease and aging cerebrum, Glia, 2, 420, 10.1002/glia.440020605 · DOI · Paper page
- Benarroch, 2013, Microglia: Multiple roles in surveillance, circuit shaping, and response to injury, Neurology, 81, 1079, 10.1212/WNL.0b013e3182a4a577 · DOI · Paper page
- Bhattacharya, 2015, Nasal application of the galantamine pro-drug memogain slows down plaque deposition and ameliorates behavior in 5× familial Alzheimer's disease mice, J. Alzheimers Dis., 46, 123, 10.3233/JAD-142421 · DOI · Paper page
- Birks, 2000, Rivastigmine for Alzheimer's disease, Cochrane Database Syst. Rev., 2, CD001191
- Blain, 2000, Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives, Presse Med., 29, 267
- Boche, 2008, Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain, Brain, 131, 3299, 10.1093/brain/awn261 · DOI · Paper page
- Boutajangout, 2010, Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model, J. Neurosci., 30, 16559, 10.1523/JNEUROSCI.4363-10.2010 · DOI · Paper page
- Brown, 2012, MG624, an alpha7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway, Angiogenesis, 15, 99, 10.1007/s10456-011-9246-9 · DOI
- Brun, 1986, Brain changes in dementia of Alzheimer's type relevant to new imaging diagnostic methods, Prog. Neuropsychopharmacol. Biol. Psychiatry, 10, 297, 10.1016/0278-5846(86)90009-6 · DOI
- Buckwalter, 2004, Modelling neuroinflammatory phenotypes in vivo, J. Neuroinflammation., 1, 10, 10.1186/1742-2094-1-10 · DOI
- Buttini, 1998, Novel role of human CD4 molecule identified in neurodegeneration, Nat. Med., 4, 441, 10.1038/nm0498-441 · DOI
- Carmeli, 2013, Demyelination in mild cognitive impairment suggests progression path to Alzheimer's disease, PLoS ONE, 8, e72759, 10.1371/journal.pone.0072759 · DOI · Paper page
- Carrasco, 2008, Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress, Neurosci. Lett., 441, 44, 10.1016/j.neulet.2008.05.111 · DOI
- Carson, 2008, Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease, Neuromolecular. Med., 10, 377, 10.1007/s12017-008-8048-8 · DOI
- Chang, 2010, NeuroHIV and use of addictive substances, Int. Rev. Neurobiol., 118, 403, 10.1016/B978-0-12-801284-0.00013-0 · DOI
- Changeux, 1998, Allosteric receptors after 30 years, Neuron, 21, 959, 10.1016/S0896-6273(00)80616-9 · DOI · Paper page
- Changeux, 2005, Allosteric mechanisms of signal transduction, Science, 308, 1424, 10.1126/science.1108595 · DOI · Paper page
- Chen, 2006, alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats, Neuropharmacology, 50, 254, 10.1016/j.neuropharm.2005.09.018 · DOI
- Cohen, 2013, A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss, J. Neurosci., 33, 6245, 10.1523/JNEUROSCI.3672-12.2013 · DOI · Paper page
- Craig, 2011, Revisiting the cholinergic hypothesis in the development of Alzheimer's disease, Neurosci. Biobehav. Rev., 35, 1397, 10.1016/j.neubiorev.2011.03.001 · DOI · Paper page
- Cudaback, 2014, Therapeutic implications of the prostaglandin pathway in Alzheimer's disease, Biochem. Pharmacol., 88, 565, 10.1016/j.bcp.2013.12.014 · DOI
- de la Torre, 2014, Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, N. Engl. J. Med., 370, 1459, 10.1056/NEJMc1402193 · DOI · Paper page
- De Simone, 2005, Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures, J. Neuroinflammation, 2, 4, 10.1186/1742-2094-2-4 · DOI
- Dhib-Jalbut, 2006, Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases, J. Neuroimmunol., 176, 198, 10.1016/j.jneuroim.2006.03.027 · DOI
- Dickson, 1993, Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease, Glia, 7, 75, 10.1002/glia.440070113 · DOI · Paper page
- Dineley, 2015, Nicotinic ACh receptors as therapeutic targets in CNS disorders, Trends Pharmacol. Sci., 36, 96, 10.1016/j.tips.2014.12.002 · DOI · Paper page
- Dore, 2006, GPCR antagonists as an alternative to COX-2 inhibitors: a case for the PGE2 EP1 receptor, Trends Pharmacol. Sci., 27, 458, 10.1016/j.tips.2006.07.001 · DOI
- Dunlop, 2009, Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b′]di pyrrole-1(2H)-carboxamide), J. Pharmacol. Exp. Ther., 328, 766, 10.1124/jpet.108.146514 · DOI
- Echeverria, 2005, Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure, Eur. J. Neurosci., 22, 2199, 10.1111/j.1460-9568.2005.04427.x · DOI · Paper page
- Echeverria, 2012, Cotinine: a potential new therapeutic agent against Alzheimer's disease, CNS Neurosci. Ther., 18, 517, 10.1111/j.1755-5949.2012.00317.x · DOI
- Echeverria, 2011, Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice, J. Alzheimers Dis., 24, 817, 10.3233/JAD-2011-102136 · DOI
- Farlow, 2012, Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, Alzheimers Dement., 8, 261, 10.1016/j.jalz.2011.09.224 · DOI · Paper page
- Feldman, 2009, Analyses of mortality risk in patients with dementia treated with galantamine, Acta Neurol. Scand., 119, 22, 10.1111/j.1600-0404.2008.01047.x · DOI
- Feldman, 2009, Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease, Int. J. Geriatr. Psychiatry, 24, 479, 10.1002/gps.2141 · DOI · Paper page
- Foster, 2001, Calcineurin links Ca2+ dysregulation with brain aging, J. Neurosci., 21, 4066, 10.1523/JNEUROSCI.21-11-04066.2001 · DOI · Paper page
- Fuxe, 1979, On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons, Pharmacol. Biochem. Behav., 10, 671, 10.1016/0091-3057(79)90319-8 · DOI
- Galvis, 2006, Expression of nicotinic acetylcholine receptors on murine alveolar macrophages, J. Mol. Neurosci., 30, 107, 10.1385/JMN:30:1:107 · DOI
- Gatson, 2015, High therapeutic potential of positive allosteric modulation of alpha7 nAChRs in a rat model of traumatic brain injury: proof-of-concept, Brain Res. Bull., 112, 35, 10.1016/j.brainresbull.2015.01.008 · DOI
- Ghezzi, 2013, Disease-modifying drugs in Alzheimer's disease, Drug Des. Devel. Ther., 7, 1471
- Gorkiewicz, 2010, Matrix metalloproteinase-9 reversibly affects the time course of NMDA-induced currents in cultured rat hippocampal neurons, Hippocampus, 20, 1105, 10.1002/hipo.20736 · DOI
- Gotz, 2010, Animal models reveal role for tau phosphorylation in human disease, Biochim. Biophys. Acta, 1802, 860, 10.1016/j.bbadis.2009.09.008 · DOI
- Gotz, 2012, Alzheimer's disease models and functional genomics-How many needles are there in the haystack?, Front. Physiol., 3, 320, 10.3389/fphys.2012.00320 · DOI
- Guo, 2012, Nicotine dynamically modulates dopamine clearance in rat striatum in vivo, Neurochem. Int., 60, 355, 10.1016/j.neuint.2012.01.022 · DOI
- Hoozemans, 2003, Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease, Curr. Drug Targets, 4, 461, 10.2174/1389450033490902 · DOI · Paper page
- Horiuchi, 2012, Amyloid beta1–42 oligomer inhibits myelin sheet formation in vitro, Neurobiol. Aging, 33, 499, 10.1016/j.neurobiolaging.2010.05.007 · DOI
- Hu, 2015, Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease, J. Clin. Pharmacol., 55, 221, 10.1002/jcph.393 · DOI
- Hurst, 2005, A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization, J. Neurosci., 25, 4396, 10.1523/JNEUROSCI.5269-04.2005 · DOI · Paper page
- Inestrosa, 2013, Nicotine prevents synaptic impairment induced by amyloid-beta oligomers through alpha7-nicotinic acetylcholine receptor activation, Neuromol. Med., 15, 549, 10.1007/s12017-013-8242-1 · DOI
- Inglese, 2005, The relation between MRI measures of inflammation and neurodegeneration in multiple sclerosis, J. Neurol. Sci., 233, 15, 10.1016/j.jns.2005.03.001 · DOI
- Ishizawa, 2003, Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice, Am. J. Pathol., 163, 1057, 10.1016/S0002-9440(10)63465-7 · DOI
- Jones, 2012, Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia, Neuropsychopharmacology, 37, 16, 10.1038/npp.2011.199 · DOI · Paper page
- Kamat, 2014, Astrocyte mediated MMP-9 activation in the synapse dysfunction: an implication in Alzheimer disease, Ther. Targets Neurol. Dis., 1, e243
- Kavanagh, 2011, Galantamine and behavior in Alzheimer disease: analysis of four trials, Acta Neurol. Scand., 124, 302, 10.1111/j.1600-0404.2011.01525.x · DOI
- Kavanagh, 2011, Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease, Curr. Alzheimer Res., 8, 175, 10.2174/156720511795256044 · DOI
- Kavanagh, 2011, Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study, J. Alzheimers Dis., 27, 521, 10.3233/JAD-2011-110417 · DOI
- Kihara, 2004, Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity, Biochem. Biophys. Res. Commun., 325, 976, 10.1016/j.bbrc.2004.10.132 · DOI
- Kihara, 1998, Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity, Brain Res., 792, 331, 10.1016/S0006-8993(98)00138-3 · DOI · Paper page
- Kosenko, 2014, Pathogenesis of Alzheimer disease: role of oxidative stress, amyloid-beta peptides, systemic ammonia and erythrocyte energy metabolism, CNS Neurol. Disord. Drug Targets, 13, 112, 10.2174/18715273113126660130 · DOI · Paper page
- Lambracht-Washington, 2013, Anti-amyloid beta to tau—based immunization: developments in immunotherapy for Alzheimer disease, Immunotargets Ther., 2013, 105, 10.2147/ITT.S31428 · DOI
- Laske, 2014, Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, N. Engl. J. Med., 370, 1459, 10.1056/NEJMc1402193 · DOI · Paper page
- Lassmann, 2007, Multiple sclerosis: is there neurodegeneration independent from inflammation?, J. Neurol. Sci., 259, 3, 10.1016/j.jns.2006.08.016 · DOI
- LaVoie, 1985, Evaluation of the effects of cotinine and nicotine-N′-oxides on the development of tumors in rats initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide, J. Natl. Cancer Inst., 75, 1075
- Lee, 2015, Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis, Neurobiol. Aging, 36, 42, 10.1016/j.neurobiolaging.2014.07.024 · DOI
- Leiser, 2009, A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits, Pharmacol. Ther., 122, 302, 10.1016/j.pharmthera.2009.03.009 · DOI · Paper page
- Li, 2014, Activation of alpha7 nicotinic acetylcholine receptor protects against oxidant stress damage through reducing vascular peroxidase-1 in a JNK signaling-dependent manner in endothelial cells, Cell Physiol. Biochem., 33, 468, 10.1159/000358627 · DOI
- Lieberman, 2013, A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia, Neuropsychopharmacology, 38, 968, 10.1038/npp.2012.259 · DOI · Paper page
- Liu, 2014, T cells promote the regeneration of neural precursor cells in the hippocampus of Alzheimer's disease mice, Neural Regen. Res., 9, 1541, 10.4103/1673-5374.139481 · DOI
- Livingstone, 2010, Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by Alpha7 nicotinic receptors and potentiated by PNU-120596, J. Mol. Neurosci., 40, 172, 10.1007/s12031-009-9232-5 · DOI
- Lloyd, 2001, Depression in late life, cognitive decline and white matter pathology in two clinico-pathologically investigated cases, Int. J. Geriatr. Psychiatry, 16, 281, 10.1002/gps.328 · DOI
- Lok, 2012, Neuregulin-1 effects on endothelial and blood–brain-barrier permeability after experimental injury, Transl. Stroke Res., 3, S119, 10.1007/s12975-012-0157-x · DOI
- Lopez-Hernandez, 2009, Positive modulation of alpha7 nAChR responses in rat hippocampal interneurons to full agonists and the alpha7-selective partial agonists, 4OH-GTS-21 and S 24795, Neuropharmacology, 56, 821, 10.1016/j.neuropharm.2009.01.011 · DOI
- Luber-Narod, 1988, Immune system associated antigens expressed by cells of the human central nervous system, Neurosci. Lett., 94, 17, 10.1016/0304-3940(88)90263-7 · DOI
- Ludwig, 2010, Localization by site-directed mutagenesis of a galantamine binding site on alpha7 nicotinic acetylcholine receptor extracellular domain, J. Recept Signal Transduct. Res., 30, 469, 10.3109/10799893.2010.505239 · DOI
- Luo, 2007, Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis, J. Clin. Invest., 117, 3306, 10.1172/JCI31763 · DOI · Paper page
- Maelicke, 2010, Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy, J. Mol. Neurosci., 40, 135, 10.1007/s12031-009-9269-5 · DOI
- Majumdar, 2008, Degradation of fibrillar forms of Alzheimer's amyloid beta-peptide by macrophages, Neurobiol. Aging, 29, 707, 10.1016/j.neurobiolaging.2006.12.001 · DOI
- Maldifassi, 2014, A new IRAK-M-mediated mechanism implicated in the anti-inflammatory effect of nicotine via alpha7 nicotinic receptors in human macrophages, PLoS ONE, 9, e108397, 10.1371/journal.pone.0108397 · DOI
- Mancardi, 1983, Fibrous astrocytes in Alzheimer's disease and senile dementia of Alzheimer's type, Acta Neuropathol., 61, 76, 10.1007/BF00688390 · DOI
- Marosova, 2014, How can viruses influence the neuroinflammation and neurodegeneration in the aged human brain, Acta Virol., 57, 273
- Martelli, 2014, The cholinergic anti-inflammatory pathway: a critical review, Auton Neurosci., 182, 65, 10.1016/j.autneu.2013.12.007 · DOI · Paper page
- McCarty, 2009, Cell adhesion and signaling networks in brain neurovascular units, Curr. Opin. Hematol., 16, 209, 10.1097/MOH.0b013e32832a07eb · DOI
- McGeer, 2010, Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy, J. Alzheimers Dis., 19, 355, 10.3233/JAD-2010-1219 · DOI · Paper page
- McGeer, 1989, Immune system response in Alzheimer's disease, Can. J. Neurol. Sci., 16, 516, 10.1017/S0317167100029863 · DOI · Paper page
- McGeer, 2000, Autotoxicity and Alzheimer disease, Arch. Neurol., 57, 789, 10.1001/archneur.57.6.789 · DOI · Paper page
- McGeer, 2001, Inflammation, autotoxicity and Alzheimer disease, Neurobiol. Aging, 22, 799, 10.1016/S0197-4580(01)00289-5 · DOI · Paper page
- McGeer, 2002, Innate immunity, local inflammation, and degenerative disease, Sci. Aging Knowledge Environ., 2002, re3, 10.1126/sageke.2002.29.re3 · DOI · Paper page
- McGeer, 2011, History of innate immunity in neurodegenerative disorders, Front. Pharmacol., 2, 77, 10.3389/fphar.2011.00077 · DOI · Paper page
- McGeer, 2013, Targeting microglia for the treatment of Alzheimer's disease, Expert Opin. Ther. Targets, 1
- McGeer, 2006, Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years, J. Alzheimers Dis., 9, 271, 10.3233/JAD-2006-9S330 · DOI · Paper page
- Michaluk, 2007, Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction, Cell Death Differ., 14, 1255, 10.1038/sj.cdd.4402141 · DOI
- Michaluk, 2007, Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity, J. Biol. Chem., 282, 16036, 10.1074/jbc.M700641200 · DOI · Paper page
- Miguel-Alvarez, 2015, Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect, Drugs Aging, 32, 139, 10.1007/s40266-015-0239-z · DOI · Paper page
- Miklossy, 2006, Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys, Exp. Neurol., 197, 275, 10.1016/j.expneurol.2005.10.034 · DOI · Paper page
- Mitew, 2010, Focal demyelination in Alzheimer's disease and transgenic mouse models, Acta Neuropathol., 119, 567, 10.1007/s00401-010-0657-2 · DOI · Paper page
- Miyauchi, 2012, Toll-like receptor (TLR) 3 as a surrogate sensor of retroviral infection in human cells, Biochem. Biophys. Res. Commun., 424, 519, 10.1016/j.bbrc.2012.06.148 · DOI
- Monod, 1965, On the nature of allosteric transitions: a plausible model, J. Mol. Biol., 12, 88, 10.1016/S0022-2836(65)80285-6 · DOI · Paper page
- Mushtaq, 2015, Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms, Saudi J. Biol. Sci., 22, 4, 10.1016/j.sjbs.2014.05.003 · DOI · Paper page
- Nacmias, 2014, Genetics of Alzheimer's disease and frontotemporal dementia, Curr. Mol. Med., 10.2174/1566524014666141010152143 · DOI
- Nagai, 1983, Choline acetyltransferase immunohistochemistry in brains of Alzheimer's disease patients and controls, Neurosci. Lett., 36, 195, 10.1016/0304-3940(83)90264-1 · DOI · Paper page
- Najem, 2014, Insulin resistance, neuroinflammation, and Alzheimer's disease, Rev. Neurosci., 25, 509, 10.1515/revneuro-2013-0050 · DOI · Paper page
- Nimmerjahn, 2009, Astrocytes going live: advances and challenges, J. Physiol., 587, 1639, 10.1113/jphysiol.2008.167171 · DOI · Paper page
- Nimmerjahn, 2005, Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo, Science, 308, 1314, 10.1126/science.1110647 · DOI · Paper page
- Nordberg, 2002, Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw), J. Neurochem., 81, 655, 10.1046/j.1471-4159.2002.00874.x · DOI · Paper page
- Norris, 2002, Calcineurin enhances L-type Ca(2+) channel activity in hippocampal neurons: increased effect with age in culture, Neuroscience, 110, 213, 10.1016/S0306-4522(01)00574-7 · DOI
- Ono, 2002, Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro, Biol. Psychiatry, 52, 880, 10.1016/S0006-3223(02)01417-8 · DOI
- Ono, 2006, The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta, Curr. Pharm. Des., 12, 4357, 10.2174/138161206778793010 · DOI · Paper page
- Overmyer, 1999, Astrogliosis and the ApoE genotype. an immunohistochemical study of postmortem human brain tissue, Dement. Geriatr. Cogn. Disord., 10, 252, 10.1159/000017128 · DOI · Paper page
- Palma, 1998, Effects of Zn2+ on wild and mutant neuronal alpha7 nicotinic receptors, Proc. Natl. Acad. Sci. U.S.A., 95, 10246, 10.1073/pnas.95.17.10246 · DOI
- Panza, 2014, Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward, Expert. Rev. Clin. Immunol., 10, 405, 10.1586/1744666X.2014.883921 · DOI
- Parachikova, 2007, Inflammatory changes parallel the early stages of Alzheimer disease, Neurobiol. Aging, 28, 1821, 10.1016/j.neurobiolaging.2006.08.014 · DOI · Paper page
- Paresce, 1997, Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells, J. Biol. Chem., 272, 29390, 10.1074/jbc.272.46.29390 · DOI · Paper page
- Paris, 2013, Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation, Eur. J. Pharmacol., 698, 145, 10.1016/j.ejphar.2012.11.017 · DOI
- Patel, 2014, Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice, Front. Aging Neurosci., 6, 162, 10.3389/fnagi.2014.00162 · DOI
- Paulson, 2008, Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease, Am. J. Pathol., 173, 762, 10.2353/ajpath.2008.080175 · DOI
- Pavlov, 2007, Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis, Crit. Care Med., 35, 1139, 10.1097/01.CCM.0000259381.56526.96 · DOI · Paper page
- Perry, 2000, Oxidative damage in Alzheimer's disease: the metabolic dimension, Int. J. Dev. Neurosci., 18, 417, 10.1016/S0736-5748(00)00006-X · DOI · Paper page
- Pooler, 2013, Tau-amyloid interactions in the rTgTauEC model of early Alzheimer's disease suggest amyloid-induced disruption of axonal projections and exacerbated axonal pathology, J. Comp. Neurol., 521, 4236, 10.1002/cne.23411 · DOI · Paper page
- Posadas, 2013, Nicotinic receptors in neurodegeneration, Curr. Neuropharmacol., 11, 298, 10.2174/1570159X11311030005 · DOI
- Raivich, 2005, Like cops on the beat: the active role of resting microglia, Trends Neurosci., 28, 571, 10.1016/j.tins.2005.09.001 · DOI · Paper page
- Rehani, 2008, Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells, Biochim. Biophys. Acta, 1783, 375, 10.1016/j.bbamcr.2007.12.003 · DOI
- Rodriguez, 2009, Astroglia in dementia and Alzheimer's disease, Cell Death Differ., 16, 378, 10.1038/cdd.2008.172 · DOI · Paper page
- Rogers, 1988, Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease, Neurobiol. Aging, 9, 339, 10.1016/S0197-4580(88)80079-4 · DOI · Paper page
- Rosas-Ballina, 2009, The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE, Mol. Med., 15, 195, 10.2119/molmed.2009.00039 · DOI · Paper page
- Rossor, 1983, Focal changes in Alzheimer's disease and cholinergic hypothesis, Lancet, 2, 465, 10.1016/S0140-6736(83)90441-5 · doi:10.1016/s0140-6736(83)90441-5
- Rostasy, 2005, Inflammation and neuroaxonal injury in multiple sclerosis and AIDS dementia complex: implications for neuroprotective treatment, Neuropediatrics, 36, 230, 10.1055/s-2005-865864 · DOI
- Roth, 2005, Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation, Biol. Res., 38, 381, 10.4067/S0716-97602005000400011 · DOI
- Saez, 2006, Production of nerve growth factor by beta-amyloid-stimulated astrocytes induces p75NTR-dependent tau hyperphosphorylation in cultured hippocampal neurons, J. Neurosci. Res., 84, 1098, 10.1002/jnr.20996 · DOI · Paper page
- Saez, 2004, Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons, In Vivo, 18, 275
- Saiga, 2012, Innate immune effectors in mycobacterial infection, Clin. Dev. Immunol., 2011, 347594
- Salomon, 1996, Nicotine inhibits amyloid formation by the beta-peptide, Biochemistry, 35, 13568, 10.1021/bi9617264 · DOI · Paper page
- Samochocki, 2003, Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors, J. Pharmacol. Exp. Ther., 305, 1024, 10.1124/jpet.102.045773 · DOI · Paper page
- Samochocki, 2000, Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR, Acta Neurol. Scand. Suppl., 176, 68, 10.1034/j.1600-0404.2000.00310.x · DOI · Paper page
- Seo, 2012, Neurovascular matrix metalloproteinases and the blood–brain barrier, Curr. Pharm. Des., 18, 3645, 10.2174/138161212802002742 · DOI · Paper page
- Sha, 2014, Active immunotherapy facilitates Abeta plaque removal following through microglial activation without obvious T cells infiltrating the CNS, J. Neuroimmunol., 274, 62, 10.1016/j.jneuroim.2014.06.008 · DOI
- Shi, 2012, Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease, Ann. Neurol., 72, 788, 10.1002/ana.23677 · DOI · Paper page
- Simard, 2006, Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease, Mol. Psychiatry, 11, 327, 10.1038/sj.mp.4001809 · DOI
- Srivareerat, 2011, Chronic nicotine restores normal Abeta levels and prevents short-term memory and E-LTP impairment in Abeta rat model of Alzheimer's disease, Neurobiol. Aging, 32, 834, 10.1016/j.neurobiolaging.2009.04.015 · DOI
- Streit, 2014, Human CNS immune senescence and neurodegeneration, Curr. Opin. Immunol., 29, 93, 10.1016/j.coi.2014.05.005 · DOI · Paper page
- Struble, 1982, Cholinergic innervation in neuritic plaques, Science, 216, 413, 10.1126/science.6803359 · DOI · Paper page
- Suzuki, 2006, Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role, J. Neurosci. Res., 83, 1461, 10.1002/jnr.20850 · DOI · Paper page
- Takeda, 2001, Roles of Toll-like receptors in innate immune responses, Genes Cells, 6, 733, 10.1046/j.1365-2443.2001.00458.x · DOI · Paper page
- Takeda, 2004, TLR signaling pathways, Semin Immunol., 16, 3, 10.1016/j.smim.2003.10.003 · DOI · Paper page
- Takeda, 2003, Toll-like receptors, Annu. Rev. Immunol., 21, 335, 10.1146/annurev.immunol.21.120601.141126 · DOI · Paper page
- Takeuchi, 1999, Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components, Immunity, 11, 443, 10.1016/S1074-7613(00)80119-3 · DOI · Paper page
- Takeuchi, 1999, TLR6: A novel member of an expanding toll-like receptor family, Gene, 231, 59, 10.1016/S0378-1119(99)00098-0 · DOI · Paper page
- Terry, 2015, R-(+) and s-(−) isomers of cotinine augment cholinergic responses in vitro and in vivo, J. Pharmacol. Exp. Ther., 352, 405, 10.1124/jpet.114.219881 · DOI
- Thomsen, 2012, The alpha7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-alpha release from microglia, J. Neuroimmunol., 251, 65, 10.1016/j.jneuroim.2012.07.006 · DOI
- Uteshev, 2002, Activation and inhibition of native neuronal alpha-bungarotoxin-sensitive nicotinic ACh receptors, Brain Res., 948, 33, 10.1016/S0006-8993(02)02946-3 · DOI
- Uteshev, 2003, Regulation of neuronal function by choline and 4OH-GTS-21 through alpha 7 nicotinic receptors, J Neurophysiol, 89, 1797, 10.1152/jn.00943.2002 · DOI · Paper page
- Velez-Fort, 2009, Functional alpha 7-containing nicotinic receptors of NG2-expressing cells in the hippocampus, Glia, 57, 1104, 10.1002/glia.20834 · DOI
- Villoslada, 2008, Immunotherapy for neurological diseases, Clin. Immunol., 128, 294, 10.1016/j.clim.2008.04.003 · DOI
- Wang, 2012, Multiple diffusivities define white matter degeneration in amnestic mild cognitive impairment and Alzheimer's disease, J. Alzheimers Dis., 30, 423, 10.3233/JAD-2012-111304 · DOI
- White, 2005, Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation, Neurobiol Dis, 18, 459, 10.1016/j.nbd.2004.12.013 · DOI · Paper page
- Whitehouse, 1986, Nicotinic acetylcholine binding sites in Alzheimer's disease, Brain Res., 371, 146, 10.1016/0006-8993(86)90819-X · DOI · Paper page
- Whitehouse, 1988, Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study, Neurology, 38, 720, 10.1212/WNL.38.5.720 · DOI · Paper page
- Whitman, 2004, Oligodendrocyte degeneration in AD, Neurobiol. Aging, 25, 33, 10.1016/j.neurobiolaging.2003.06.001 · DOI
- Williams, 2012, Intrinsically low open probability of alpha7 nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures, Mol. Pharmacol., 82, 746, 10.1124/mol.112.080317 · DOI
- Williams, 2011, Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations, Biochem. Pharmacol., 82, 915, 10.1016/j.bcp.2011.05.001 · DOI · Paper page
- Winterer, 2013, Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study, Neuropharmacology, 64, 197, 10.1016/j.neuropharm.2012.06.040 · DOI
- Wyss-Coray, 2005, Killing pain, killing neurons?, Nat. Med., 11, 472, 10.1038/nm0505-472 · DOI
- Wyss-Coray, 2001, Key signaling pathways regulate the biological activities and accumulation of amyloid-beta, Neurobiol. Aging, 22, 967, 10.1016/S0197-4580(01)00305-0 · DOI
- Wyss-Coray, 2000, Ibuprofen, inflammation and Alzheimer disease, Nat. Med., 6, 973, 10.1038/79661 · DOI
- Xia, 2015, Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines, Biochim. Biophys. Acta, 1852, 913, 10.1016/j.bbadis.2014.12.017 · DOI
- Xu, 2014, Amyloid precursor protein at node of Ranvier modulates nodal formation, Cell Adhesion Migr., 8, 396, 10.4161/cam.28802 · DOI
- Yong, 2010, Promoting remyelination by reducing an inhibitory microenvironment, Rinsho Shinkeigaku, 50, 869, 10.5692/clinicalneurol.50.869 · DOI
- Yong, 2010, The interplay between the immune and central nervous systems in neuronal injury, Neurology 74 Suppl, 1, S9
- Young, 2013, Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia, Biochem. Pharmacol., 86, 1122, 10.1016/j.bcp.2013.06.031 · DOI · Paper page
- Zamani, 2001, Nicotine and its interaction with beta-amyloid protein: a short review, Biol. Psychiatry, 49, 221, 10.1016/S0006-3223(00)01108-2 · DOI
- Zandi, 2002, Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study, Neurology, 59, 880, 10.1212/WNL.59.6.880 · DOI · Paper page
Cited by
González-Reyes, R. E., Nava-Mesa, M. O., Vargas-Sánchez, K., Ariza-Salamanca, D., & Mora-Muñoz, L. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00427 · Cited by 527
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Libro, R., Giacoppo, S., Soundara Rajan, T., Bramanti, P., & Mazzon, E. (2016) · Molecules · doi:10.3390/molecules21040518 · Cited by 107
Tau accumulation triggers STAT1‐dependent memory deficits by suppressing NMDA receptor expression
Li, X., Hong, X., Wang, Y., Zhang, S., Zhang, J., Li, X., Liu, Y., Sun, D., Feng, Q., Ye, J., et al. (2019) · The EMBO Reports · doi:10.15252/embr.201847202 · Cited by 81
Xu, Z.-Q., Zhang, W.-J., Su, D.-F., Zhang, G.-Q., & Miao, C.-Y. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-273 · Cited by 60
Nociplastic pain: the prominent role of non-neuronal cells in central and peripheral sensitization
Lai, W., Tang, X., Chen, S., Zhou, Y., Qi, Z., Cao, M., Yuan, C., Yu, J., & Wen, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1677310 · Cited by 5
Metadata
- Authors
- Echeverria, V., Yarkov, A., & Aliev, G.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 144
- Pages
- 142-157
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W2234380999
- Cited by
- 91
- References
- 63
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- University San Sebastian, Chile (1150194)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.pneurobio.2016.01.002
- The paper
- Echeverria, V., Yarkov, A., & Aliev, G. (2016). Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2016.01.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.